NuCana (NASDAQ:NCNA) Stock Price Down 2.9% – What’s Next?

NuCana PLC Sponsored ADR (NASDAQ:NCNA) shares dropped 2.9% during trading on Thursday. The company traded as low as $0.97 and last traded at $1.02. Approximately 55,147 shares changed hands during trading, a decline of 78% from the average session volume of 253,137 shares. The stock had previously closed at $1.05.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of NuCana in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, NuCana presently has a consensus rating of “Sell”.

NuCana Trading Down 2.9%

The company has a market capitalization of $4.24 million, a P/E ratio of -0.27 and a beta of 2.30. The company’s fifty day moving average is $1.34 and its 200 day moving average is $1.62.

NuCana (NASDAQ:NCNA) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($2.65) by $1.66.

About NuCana

NuCana plc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. The company applies its ProTide technology platform to existing nucleoside analogues, with the goal of improving their delivery into tumor cells, increasing anticancer activity and overcoming mechanisms of drug resistance.

NuCana’s pipeline has included Acelarin (NUC-1031), a ProTide-based version of gemcitabine investigated in several solid tumors, including pancreatic, biliary tract and ovarian cancers.